Evidence map›Paper›PMID 39653387›Full record

ArticleJournal of medical genetics2025

Retrospective study on the utility of optical genome mapping as a follow-up method in genetic diagnostics.

Paul Dremsek, Anna Schachner, Theresa Reischer, Elisabeth Krampl-Bettelheim, Dieter Bettelheim, Sybille Vrabel, Zoja Delissen, Mateja Pfeifer, Beatrix Weil, Robert Bajtela and 3 more

Abstract read
In one paragraph

Article in Journal of medical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Paul DremsekCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria paul.dremsek@meduniwien.ac.at.ORCID 0000-0001-9387-1216
Anna SchachnerCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Theresa ReischerDepartment of Obstetrics and Gynaecology, Medical University of Vienna, Wien, Austria.
Elisabeth Krampl-BettelheimFetoMed-Fetal Medicine Clinic, Vienna, Austria.
Dieter BettelheimDepartment of Obstetrics and Gynaecology, Medical University of Vienna, Wien, Austria.
Sybille VrabelCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Zoja DelissenCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Mateja PfeiferCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Beatrix WeilCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Robert BajtelaCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Markus HengstschlägerCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Franco LacconeCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.
Jürgen NeesenCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Wien, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent standard-of-care (SOC) methods for genetic testing are capable of resolving deletions and sequence variants, but they mostly fail to provide information on the breakpoints of duplications and balanced structural variants (SV). However, this information may be necessary for their clinical assessment, especially if the carrier's phenotype is difficult to assess and/or carrier analysis of relatives is not viable. A promising approach to solving such challenging cases arises with access to optical genome mapping (OGM) but has not been systematically explored as of yet.

methodsIn this retrospective study, we evaluated diagnostic cases from a 1-year period (2023) in which an SV discovery by SOC methods (microarray, karyotyping and whole-exome sequencing) was followed up by OGM, with the objective to unlock clinically relevant information about the SV.

resultsSeven cases were shown by SOC methods to bear potential pathogenic SVs and were consequently followed up by OGM. Of these, six were solved by the additional use of OGM alone. One case required sequencing after OGM analysis to further specify the SV's breakpoints. In all seven cases, OGM was crucial for determining the clinical relevance of the detected SV.

conclusionThis study describes the use of OGM as a valuable method for characterising duplications and balanced SVs. Often, this additional information does not add to the quality of a clinical report. However, for a subset of patients, these data are critical, especially in the prenatal setting or when no familial analyses are possible.

Indexed as

Chromosome MappingGenetic TestingExome SequencingFemaleFollow-Up StudiesGenome, HumanGenomic Structural VariationHumansKaryotypingMaleRetrospective StudiesChromosome AberrationsCytogeneticsGenetic TestingPrenatal Diagnosis

Identifiers

PMID39653387
PMCPMC11877032

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.